Is Telix Pharmaceuticals Limited (TLX) a Buy, Sell, or Hold?
NASDAQ : TLX
Telix Pharmaceuticals Limited
$10.22 USD
-$0.29 (-2.76%)
- Volume
- 83.11K
- Average Volume
- 164.86K
- Market Capitalization
- $3.46B
- P/E Ratio
- -456.70
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $14.27
- Year Low
- $6.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.43
Company Overview
NASDAQ
Christian Behrenbruch
Biotechnology
Healthcare
TLX
1136
AU
USD
Liquidity Metrics
1.12
1.43
1.27
0.61
0.00
Sales & Valuation
$1.21B
4.06
7.97
-63.94
-0.23
Profitability
-$0.0316
-$10.69M
-0.89%
-0.65%
-1.72%
-0.61%
P/E Metrics
-456.70
3.76
3.76
Analyst Price Target & Rating
$18.00
$18.00
$18.00
1/5
5 Analysts
-43.22%
Financial Health Scores
3.96
3/9
$147.8M
$1.77B
$1.15B
$124.36M
Key Metrics (TTM)
$5.45B
4.46
147.04
1.43
-1.72%
1.77%
-0.22%
-1.56%
30 days
Company Executives
| Name | Title |
|---|---|
| Christian Behrenbruch GAICD | Co-Founder, MD, Group Chief Executive Officer & Executive Director |
| David N. Cade MBBS | Group Chief Medical Officer |
| Christian Krautkramer | Group General Counsel |
| Craig Ulrick | Chief Information Officer |
| Darren Patti | Group Chief Operating Officer |
| Meredith Crowe BDES | Senior Vice President of Global People & Culture |
| Thomas Fromm | Vice President of Sales |
| Darren Smith FCPA | Group Chief Financial Officer |
| Kyahn Williamson | Senior Vice President of Corporate Communications & Investor Relations |
| Paul Schaffer | SVP of Research & Development |
Poll Results
No votes yet today — be the first to share your view!
About Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The com ... pany is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
2026-07-22 10:56:13
The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
2026-07-21 17:00:00
MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix's first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study's scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a “theranostic” approach.
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
2026-07-20 19:31:00
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
2026-07-20 17:00:00
MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or recurrent ccRCC.
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
2026-07-15 16:20:00
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent's Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent's Hospital in Sydney, Australia.
FDA Alignment to Advance ProstACT Global Phase 3 Trial
2026-07-01 21:31:00
MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”) today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer.
2026-06-30 01:32:09
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
2026-06-22 17:40:00
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.
Frequently Asked Questions
-
What is the current Telix Pharmaceuticals Limited (TLX) stock price?
-
Telix Pharmaceuticals Limited(NASDAQ:TLX) stock price is $10.22 in the last trading session. During the trading session, TLX stock reached the peak price of $14.27 while $6.28 was the lowest point it dropped to. The percentage change in TLX stock occurred in the recent session was --2.76% while the dollar amount for the price change in TLX stock was -$0.29.
-
TLX's industry and sector of operation?
-
The NASDAQ listed TLX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TLX?
-
Christian Behrenbruch GAICD | Co-Founder, MD, Group Chief Executive Officer & Executive Director
David N. Cade MBBS | Group Chief Medical Officer
Christian Krautkramer | Group General Counsel
Craig Ulrick | Chief Information Officer
Darren Patti | Group Chief Operating Officer -
How many employees does TLX have?
-
Number of TLX employees currently stands at 1136. TLX operates from 55 Flemington Road, North Melbourne, VIC 3051, AU.
-
Link for TLX official website?
-
Official Website of TLX is: https://telixpharma.com
-
How do I contact TLX?
-
TLX could be contacted at phone #61 3 9093 3855 and can also be accessed through its website. TLX operates from 55 Flemington Road, North Melbourne, VIC 3051, AU.
-
How many shares of TLX are traded daily?
-
The average number of TLX shares traded daily for last 3 months was 164.86K.
-
What is the market cap of TLX currently?
-
The market value of TLX currently stands at $3.46B with its latest stock price at $10.22